A. ART is recommended for all viremic patients with established HIV infection regardless of CD4 cell count. B. Initiation of ART is recommended as soon as possible in the setting of acute HIV infection. C. Once a high CD4 count level is achieved, early ART treatment should discontinued. D. The initiation of ART is recommended for patients who have persistent undetectable viral load without ART but have declining CD4 cell counts.

A. Monitor her CD4 levels until they drop below 350 cells/mm³ and then initiate treatment. B. Initiate treatment with tenofovir (TDF)/emtricitabine (FTC) for 6 months, then add rilpivirine if FH's viral load does not stay below 100 000. C. Initiate treatment with the fixed dose combination of TDF/FTC/elvitegravir/cobicistat until FH is clinically stable, then consider a drug holiday. D. Initiate treatment with darunavir/ritonavir plus TDF/FTC.

A. ABC/3TC requires HLA-B*5701 testing prior to treatment whereas TDF/TAF/FTC does not. B. Only FTC is active against hepatitis B virus, whereas both ABC and 3TC are active against hepatitis B virus. C. ABC/3TC has a higher risk of renal and bone toxicity, while TDF/TAF/FTC has a higher cardiovascular event risk. D. ABC/3TC is available in multiple co-formulated single tablet regimens, whereas TDF/FTC is only available in 2 other co-formulated (none for TAF/FTC).

A. Antacids and proton pump inhibitors B. Statins and benzodiazepines C. PDE-5 inhibitors and corticosteroids D. Ergot derivatives and calcium channel blockers